The Ministry said it approved the nine proposals following recommendations of the Foreign Investment Promotion Board (FIPB).
Of the nine that have been approved, Hospira Pte Ltd, Singapore proposal entails foreign investment worth Rs 650 crore. The proposal related to post facto approval for already subscribed equity share of Hospira India Pvt Ltd, Tamil Nadu.
It also proposes fresh equity infusion in Hospira Healthcare India Pvt Ltd, Tamil Nadu.
Westbridge Crossover Fund LLC, Mauritius has got permission for issuance of the warrants convertible into equity shares. The proposal entails investment worth Rs 100 crore.
Also Read
A Singaporean subsidiary of the UK-based GlaxoSmithKline proposes to buy 24.33 per cent stake, or 2.06 crore equity shares, in GlaxoSmithKline Pharmaceuticals via an open offer.
The acquisition would result in foreign exchange inflows to the tune of Rs 6,400 crore, sources said.
Other investment proposals that have been cleared (based on the recommendations of the January 13 FIPB meeting), include that of Indo-German Steel Hub LLP, Golden Invest Pte Ltd, Singapore and B Braun Singapore Pte Ltd, Singapore.
Decision on five investment applications has been deferred and four kept in abeyance, it added.
The Ministry also recommended that the proposal of Prizm Payments Services be considered by the CCEA.
The proposal is for acquisition of 100 per cent equity stake of Prizm Payment Services from resident and non-residents shareholders by Hitachi Consulting Software Services and Hitachi Ltd.